'MECCA': A developmental, dose-intensive, non-cross-resistant platinum- based chemotherapy for advanced ovarian cancer

Gynecologic Oncology

Volumn 63, Issue 3, 1996, Pages 345-351

  Hoskins, P J ^a   Swenerton, K D ^a   Pike, J A ^a   McMurtrie, E M ^a   Lee, N ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CREATININE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; MITOMYCIN C;

ABDOMINAL RADIOTHERAPY; ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS RESISTANCE; DOSE RESPONSE; FEMALE; HEART FAILURE; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; OVARY CANCER; PRIORITY JOURNAL; SURVIVAL; TREATMENT OUTCOME;

EID: 0030561491     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1996.0334     Document Type: Article

References (28)

1. 1. Neijt, J. P., ten Bokkel Huinink, W. W., van der Burg, M. E. L., van Oosterom, A. T., Willemse, P. H. B., Vermorken, J. B., Van Lindert, A. C. M., Heintz, A. P. M., Aartsen, E., van Lent, M., Trimbos, J. B., and de Meijer, A. J. Long term survival in ovarian cancer, Eur. J. Cancer 27, 1367-1372 (1991).
2. 2. Hoskins, P. J., O'Reilly, S. E., Swenerton, K. D., Spinelli, J. J., Fairey, R. N., and Benedet, J. L. Ten year outcome of patients with advanced epithelial ovarian carcinoma treated with cisplatin-based multimodality therapy, J. Clin. Oncol. 10, 1561-1568 (1992).
3. 3. Sutton, G. P., Stehamn, F. B., Einhorn, L. H., Roth, L. M., Blessing, J. A., and Ehrlich, C. E. Ten year follow up of patients receiving cisplatin, doxorubicin and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma, J. Clin. Oncol. 7, 223-229 (1989).
4. 4. Hainsworth, J. D., Grosh, W. W., Burnett, L. S., Jones, H. W., Wolff, S. N., and Greco, F. A. Advanced ovarian cancer: Long term results of treatment with intensive cisplatin-based chemotherapy of brief duration, Ann. Intern. Med. 108, 165-170 (1988).
5. 5. Levin, L., and Hryniuk, W. M. Dose intensity analysis of chemotherapy regimens in ovarian carcinoma, J. Clin. Oncol. 5, 756-767 (1987).
6. 6. Goldie, J. H., and Coldman, A. J. A mathematical model for relating sensitivity of their tumors to their spontaneous mutation rate, Cancer Treat. Rep. 63, 1727-1735 (1979).
7. 7. Hoskins, P. J., Swenerton, K. D., and McMurtrie, E. A phase II trial of mitomycin in patients with epithelial ovarian carcinoma resistant to cisplatin or carboplatin, Am. J. Clin. Oncol. 13, 416-419 (1990).
8. 8. Kuhnle, H., Meerpohl, Hg., Lenaz, L., Achterrath, W., Pohl, J., Roben, S., Alfub, S., Pfleiderer, A., and Kuhn, W. Etoposide in cisplatin-refractory ovarian cancer, Proc. Am. Soc. Clin. Oncol. 7, 137 (1988). [Abstr. 527]
9. 9. Slevin, M. L., Clark, P. I., Joel, S. P., Thompson, P., Talbot, D., Price, C., and Wrigley, P. F. M. A randomized trial to examine the effect of more extended scheduling of etoposide administration in small cell lung cancer (SCLC), Proc. Am. Soc. Clin. Oncol. 8, 236 (1989). [Abstr. 921]
10. 10. Skipper, H. E. Dose intensity versus total dose of chemotherapy: An experimental basis, in Important advances in oncology (V. T. De Vita, S. Hullman, and S. A. Rosenberg, Eds.), Lippincott, Philadelphia, pp. 43-64 (1990).
11. 11. Durand, R. E., and Goldie, J. H. Interaction of etoposide and cisplatin in an in vitro tumor model, Cancer Treat. Rep. 71, 673-679 (1987).
12. 12. Connors, J. M., and Klimo, P. MACOB-B chemotherapy for malignant lymphomas and related conditions: 1987 update and additional observations, Semin. Haematol. 25, 41-46 (1988).
13. 13. Aisner, J., Tchekmedyian, N. S., Moody, M., and Tait, N. High dose megestrol acetate for the treatment of advanced breast cancer: Dose and toxicities, Semin. Haematol. 24, 48-55 (1987).
14. 14. Pannuti, F., Martoni, A., Di Marco, A. R., Pianna, E., Saccani, F., Becchi, G., Mattioli, G., Barbanti, F., Marra, G. A., Persiani, W., Cacciari, L., Spagnolo, F., Palerizona, D., and Rochetta, G. Prospective, randomized clinical trial of two different high dosages of medroxyprogesterone acetate (MAP) in the treatment of metastatic breast cancer, Eur. J. Cancer 15, 593-601 (1978).
15. 15. Durand, R. E. Synergism of cisplatin and mitomycin C in sensitive and resistant cell subpopulations of a tumor model, Int. J. Cancer 44, 911-917 (1989).
16. 16. Hande, K. R. Pharmacologic-based dosing of carboplatin: A better method, J. Clin. Oncol. 11, 2295-2296 (1993).
17. 17. Kalbfleisch, J. D., and Prentice, R. L. The statistical analysis of failure time data, Wiley, New York, (1980).
18. 18. Advanced Ovarian Cancer Trialists Group. Chemotherapy in advanced ovarian cancer: an overview of randomized clinical trials, Br. Med. J. 303, 884-893 (1991).
19. 19. McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., Clarke-Pearson, D. L., and Davidson, M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer, N. Engl. J. Med. 334, 1-6 (1996).
20. 20. Van den Burg, M. E. L., Van Lent, M., Buyse, M., Kobierska, A., Colombo, N., Favalli, G., Lacave, A. J., Nardi, M., Renard, J., and Pecorelli, S. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer, N. Engl. J. Med. 332, 629-634 (1995).
21. 21. Eisenhauer, E. A., ten Bokkel Huinink, W. W., Swenerton, K. D., Giann, L., Myles, J., van der Burg, M. E. L., Kerr, I., Vermorken, J. B., Buser, B., Colombo, N., Bacon, M., Santabarbara, P., Onetto, N., Winograd, B., and Canetta, R. European-Canadian trial of paclitaxel in relapsed ovarian cancer: High versus low dose and long versus short infusion, J. Clin. Oncol. 12, 2654-2666 (1994).
22. 22. Hoskins, P. J., and Swenerton, K. D. Oral etoposide (VP16) is active against platinum resistant epithelial ovarian cancer, J. Clin. Oncol. 12, 60-63 (1994).
23. 23. Maksymiuk, A. W., Jett, J. R., Earle, J. D., Su, J. Q., Diegert, F. A., Mailliard, J. A., Kardinal, G., Krook, J. E., Veeder, M. H., Wiesenfeld, M., Tschetter, L. K., and Levitt, R. Sequencing and schedule effects of cisplatin plus etoposide in small cell lung cancer: Results of a north central cancer treatment group randomized clinical trial, J. Clin. Oncol. 12, 70-76 (1994).
24. 24. Hempling, R. E., Piver, M. S., Baker, T. R., and O'Neill Mullen, C. Lack of activity of 5-fluorouracil plus mitomycin C as salvage therapy in cisplatin resistant epithelial ovarian cancer: Results of a phase II trial, Eur. J. Gynaecol. Oncol. 25, 165-169 (1994).
25. 25. Reichman, B., Markman, M., Hakes, T., Rubin, S., Jones, W., Curtin, J., Barakat, R., Almadrones, L., Lewis, J. L., and Hoskins, W. Mitomycin C plus a 3 day continuous intravenous infusion of 5 fluorouracil: An inactive salvage regimen for platinum-resistant ovarian carcinoma, Gynecol. Oncol. 50, 30-33 (1993).
26. 26. Arriagada, R., Le Chevalier, T., Pignon, J-P., Reviere, A., Mannet, I., Chomy, P., Tuchais, C., Tarayre, M., and Ruffle, P. Initial chemotherapeutic doses and survival in patients with limited small cell lung cancer, N. Engl. J. Med. 329, 1848-1852 (1993).
27. 27. Ihde, D. C., Mulshine, J. L., Kramer, B. S., Steinberg, S. M., Linnoila, R. I., Gazdar, A. F., Edison, M., Phelps, R. M., Lesar, M., Phares, J. C., Grayson, J., Minna, J. D., and Johnson, B. E. Prospective randomized comparison of high-dose and standard-dose cisplatin chemotherapy in patients with extensive stage small cell lung cancer, J. Clin. Oncol. 12, 2022-2034 (1994).
28. 28. Hoskins, P. J. Treatment of advanced epithelial ovarian cancer, Crit. Rev. Oncol. Hematol. 20, 41-59 (1995).